Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2023 / Sep / Flight Path
Oncology Digital and computational pathology Technology and innovation Quality assurance and quality control Oncology Opinion and Personal Narratives

Flight Path

If we work together, we can stop all diagnoses falling under the radar

By Joseph Mossel 09/22/2023 Opinion 4 min read

Share

Between the years 2000 and 2010 – if you exclude September 11, 2001 – there were 250 airline fatalities in the US (1). And between 2010 and 2020 – there were only two (1). Evidently, the airline industry realized airline fatalities were unacceptable – and so damaging to the industry that relevant technology was needed to curb mortality. Interestingly, airline industries don’t compete against each other. Safety is taken as a given.

Why is it considered acceptable that there are misdiagnoses in our industry? Everyone knows that it happens – and tolerates it. Consider this: the airline industry didn’t set themselves a goal to reduce fatalities; they said zero fatalities. And I think the same kind of goal should be set for cancer diagnosis. With AI, we can reach zero diagnostic error. We have the technology, but that is not enough – we also need adoption within clinical practice. Payers need to reimburse. Regulators need to work with the industry, clinicians, and pathologists. In short, it really does require an industry wide effort to achieve this goal.

We have direct access to misdiagnosis data because we deploy our algorithms in pathology labs where they’re used on a day-to-day basis. The normal range of misdiagnosis ranges between two to three percent at excellent labs – but it can go as high as 10 percent (especially in labs that lack subspecialists). If your cancer is misdiagnosed, it’s very likely to progress further and become more severe. The treatment is going to be more aggressive, mortality goes up, and the cost of the healthcare system also rises. It’s a lose-lose situation for everyone involved. We also need to understand that this is happening because of technological and resource limitations. It’s not possible for pathology labs to have three pathologists investigating every case. We need something more…

Our AI algorithms are trained by pathologists, for pathologists – and there are two ways you can deploy them in the lab. First, as a pathologists’ assistant. The algorithm can act as a virtual fellow, where it can review the case in advance and fill out a draft of the report. This way, the chances of a pathologist missing anything is reduced. The algorithms are very objective and can conduct day-to-day tasks, such as measurements and quantifications without getting tired. Over time, pathologists will start to develop confidence in algorithms’ performance and they will be able to work faster – by up to 60 percent. Second, the algorithms can be used in places where it wouldn’t be economical to have an actual human pathologist review the case. So, you can do triage of cases earlier on and make sure that the more urgent cases reach the top of the pile. You can preorder IHC staining to reduce turnaround time. In general, you can plug in the technology at different decision points in the slide preparation phase to make the process more efficient. 

Our algorithms help reduce diagnostic error because they’re extremely accurate – trained on huge datasets. Not only can they accurately detect cancer, but also help differentiate between different cancer subtypes. For example, the technology can tell the difference between invasive lobular carcinoma and invasive ductal carcinoma – or between high and low grade ductal carcinoma in situ. The algorithm can also help detect non-cancerous features, such as microcalcifications, breast biopsies, and perineural invasion. But perhaps the most exciting thing about these algorithms is the way they contribute to health equity; I can see the technology being deployed as part of standard practice in every pathology lab worldwide. 

For this technology to actually become prevalent, it’s critical that physicians and pathologists recognize the value and actively want to use it. Whenever we let pathologists play around with a new technology, they are almost always eager to deploy it in their labs. Regardless, there are still barriers. First of all, we need to acknowledge the importance of regulatory frameworks – and recognize that AI introduces new challenges for regulatory science. Agencies, the industry, and physicians need to work together to accelerate the deployment of this technology; we owe it to patients. The other piece of the puzzle is the economic model. How do we pay for this technology? Again, we need to have a big conversation with all stakeholders.

The use of biopsy revolutionized the field of pathology in terms of diagnostics, and also in terms of predictive power of pathology. This advance has become completely standard. I hope we will soon be able to say the same about AI.

Coming full circle, I’ll finish with a final call to action for zero diagnostic error. 

We need to see misdiagnosis as something that went terribly wrong – because we can prevent it from happening. Clinicians, pathologists, healthcare providers, payers, and regulators need to work together to achieve this vision. Though I don’t think it’s something that is achievable overnight, within a decade I believe we can transform cancer diagnostics to achieve much higher levels of accuracy.

Credit: Images sourced from Unsplash.com

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Airlines for America (2022). Available at: https://bit.ly/3t5la6Y

About the Author(s)

Joseph Mossel

Co-Founder and CEO of Ibex Medical Analytics, Tel Aviv, Israel.

More Articles by Joseph Mossel

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Global Referral
Digital and computational pathology
Global Referral

January 12, 2024

10 min read

How digital pathology is transforming the delivery of remote second opinions

Cracking Colon Cancer
Digital and computational pathology
Cracking Colon Cancer

January 25, 2024

1 min read

How a new clinically approved AI-based tool enables rapid microsatellite instability detection

The (Pathology) IT Crowd?
Digital and computational pathology
The (Pathology) IT Crowd?

December 30, 2021

5 min read

The pathologist’s guide to IT considerations for digitization

Defining the Next Generation of NGS
Digital and computational pathology
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.